source
- Abivax shares surge as worries subside over immune drug’s cancer riskAccording to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.BioPharma Dive · 1mo ago↗ source
- FDA says Zyn can market its pouches as safer than cigarettesThe influence of the alcohol industry on policy, AI Claude for scientists, and more health news from Morning RoundsSTAT · 1mo ago↗ source
- STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patientsThe FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.STAT · 1mo ago